Glaukos Corporation (GKOS)
Summary
Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally?
GKOS shares surge 36.8% in six months, fueled by strong sales, iDose TR and Epioxa expansion, higher guidance and promising clinical developments.
Glaukos: The Second J-Code Rewrites The Risk Math
Glaukos is transitioning from a single-product reimbursement story to a diversified ophthalmic pharmaceutical platform with two J-coded drugs and strong operating leverage. Q2 net sales grew 50% YoY to $185.6M, driven by iDose TR and the Epioxa launch, with non-GAAP gross margin reaching 85% and breakeven P&L. Management raised 2026 net sales guidance to $680–700M, with iDose TR sales expected at $275–280M and corneal health growth of 20%+.
Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal
GKOS expands its retinal pipeline with a licensing deal for RO-104 and exclusive RevMod platform rights, even as shares decline 6.3% following the news.
Glaukos Corporation Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 56 | $5,905.38 | $9,401.84 | $3,496.46 | 59.21% |
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 6,292 | $879,430 | $1.06M | $176,933.88 | 20.12% |
| PER Paul E. Rasmussen SIT INVESTMENT ASSOCIATES Inc. | 72,305 | $7.42M | $11.87M | $4.45M | 59.92% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 117 | $12,674.97 | $19,643.13 | $6,968.16 | 54.98% |
 Vaughan Nelson Vaughan Nelson Investment Management LP | 416,231 | $58.17M | $69.08M | $10.91M | 18.75% |
Glaukos Corporation Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| TS Tom Stephan Stifel | 199.92 | $31,353.28 | $32,896.66 | $1,543.38 | 4.92% |
Glaukos Corporation (GKOS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Glaukos Corporation ever had a stock split?
Glaukos Corporation Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | Thomas William Burns CEO | NYSE Exchange | 377322102 CUSIP |
| US Country | 1,094 Employees | - Last Dividend | - Last Split | 25 Jun 2015 IPO Date |
Overview
Glaukos Corporation stands as a pioneering entity within the ophthalmic pharmaceutical and medical technology sector, dedicated to crafting innovative treatments for a spectrum of eye diseases. This includes glaucoma, corneal disorders, and retinal diseases. Founded in 1998 and based in Aliso Viejo, California, the corporation not only embarks on research and development but also actively markets its breakthrough products globally. Their strategy encompasses both direct sales organizations within the United States and partnerships with distributors on an international scale, showcasing their commitment to addressing prevalent ocular conditions worldwide.
Products and Services
iStent and iStent inject W micro-bypass stents: Tailored for individuals undergoing cataract surgery, these innovative micro-bypass stents are engineered to enhance aqueous humor outflow. They specifically target mild-to-moderate open-angle glaucoma, aiming to alleviate intraocular pressure and mitigate the disease's progression. The iStent technology represents a significant advancement in glaucoma management, providing a minimally invasive solution to patients grappling with this chronic condition.
iStent Infinite: This device is designed for the treatment of glaucoma patients whose condition remains uncontrolled despite previous medical and surgical interventions. The iStent Infinite system underscores Glaukos Corporation's dedication to developing solutions for more severe stages of glaucoma, offering hope to those with limited treatment options. Its application in managing uncontrolled glaucoma demonstrates the company's innovative approach to tackling the complexities of this eye disease.
iDose TR: Featuring as an intracameral procedural pharmaceutical therapy, iDose TR is aimed at reducing intraocular pressure in patients diagnosed with open-angle glaucoma or ocular hypertension. This product represents a cutting-edge development in glaucoma treatment, promising a novel, sustained delivery method for therapeutics directly into the eye. It exemplifies Glaukos Corporation's commitment to advancing glaucoma care through innovative drug delivery systems.
Contact Information
